Compound ID | 1051
Class: Ansamycin
Spectrum of activity: | Gram-positive & Gram-negative |
Details of activity: | Broad spectrum of resistance against gram +ve and -ve bacteria |
Institute where first reported: | Pfizer Inc |
Year first mentioned: | 1976 |
Highest developmental phase: | Preclinical |
Development status: | Inactive |
External links: | |
Citations: |
|